Internal Reference Number: FOI_8263
Date Request Received: 06/11/2024 00:00:00
Date Request Replied To: 12/11/2024 00:00:00
This response was sent via: By Email
Request Summary: Semaglutide
Request Category: Media
| Question Number 1: Please see my Freedom of Information request below. Can you please provide me with any details you can on: - The number of people who have attended A&E and given Semaglutide as a reason for their visit, where there drug was indicated for weight management - in every year between 2022 and 2024. Please give a figure for each year. Semaglutide also goes under brand names such as Ozempic, Saxenda, Rybelsus and Wegovy 鈥� can you please include these names in your records also. | |
| Answer To Question 1: Please see our response to this FOI in the Excel spreadsheet attached. To accompany this answer to question 1 please also see the documents listed below:  12581 - FOI_8263 - Semaglutide FOR ISSUE.xlsx | |
| Question Number 2: Please break the figures down to give details of the complications patients presented with as a result of their use of Semaglutide. | |
| Answer To Question 2: Please see attached | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at SA国际传媒 Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
